Literature DB >> 21584790

[Neuromuscular signal transmission in adulthood. Current facets of acquired and hereditary disorders].

A Abicht1, S Kröger, B Schoser.   

Abstract

The availability of early diagnosis and modern effective therapies has reduced mortality and disability linked to late-onset acquired or hereditary neuromuscular transmission disorders. Nevertheless, identification of the pathogenesis of these diseases remains a challenge. In addition to non-specific and fluctuating presenting symptoms current diagnostic work-up strategies include electrophysiology, antibody measurements and less frequently molecular genetics. For differential diagnostic purposes there is an increasing demand for improving awareness concerning late-onset congenital myasthenic syndromes (CMS) which are rare but nevertheless symptomatically treatable diseases. Especially in seronegative myasthenic syndromes, molecular genetic analyses of CMS genes should be integrated into the differential diagnostic work-up. Therefore, some facets of neuromuscular synaptogenesis in the context of seronegative acquired myasthenic syndromes and recently uncovered congenital myasthenic syndromes are reviewed.

Entities:  

Mesh:

Year:  2011        PMID: 21584790     DOI: 10.1007/s00115-010-2969-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  19 in total

Review 1.  The congenital myasthenic syndromes.

Authors:  Jackie Palace; David Beeson
Journal:  J Neuroimmunol       Date:  2008-08-15       Impact factor: 3.478

2.  Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury.

Authors:  D M Valenzuela; T N Stitt; P S DiStefano; E Rojas; K Mattsson; D L Compton; L Nuñez; J S Park; J L Stark; D R Gies
Journal:  Neuron       Date:  1995-09       Impact factor: 17.173

3.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.

Authors:  Jan Senderek; Juliane S Müller; Marina Dusl; Tim M Strom; Velina Guergueltcheva; Irmgard Diepolder; Steven H Laval; Susan Maxwell; Judy Cossins; Sabine Krause; Nuria Muelas; Juan J Vilchez; Jaume Colomer; Cecilia Jimenez Mallebrera; Andres Nascimento; Shahriar Nafissi; Ariana Kariminejad; Yalda Nilipour; Bita Bozorgmehr; Hossein Najmabadi; Carmelo Rodolico; Jörn P Sieb; Ortrud K Steinlein; Beate Schlotter; Benedikt Schoser; Janbernd Kirschner; Ralf Herrmann; Thomas Voit; Anders Oldfors; Christopher Lindbergh; Andoni Urtizberea; Maja von der Hagen; Angela Hübner; Jacqueline Palace; Kate Bushby; Volker Straub; David Beeson; Angela Abicht; Hanns Lochmüller
Journal:  Am J Hum Genet       Date:  2011-02-11       Impact factor: 11.025

5.  Crystal structure of the frizzled-like cysteine-rich domain of the receptor tyrosine kinase MuSK.

Authors:  Amy L Stiegler; Steven J Burden; Stevan R Hubbard
Journal:  J Mol Biol       Date:  2009-08-04       Impact factor: 5.469

6.  Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis.

Authors:  Neli Boneva; Melinee Frenkian-Cuvelier; Jocelyne Bidault; Talma Brenner; Sonia Berrih-Aknin
Journal:  J Neuroimmunol       Date:  2006-07-20       Impact factor: 3.478

7.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

8.  LRP4 serves as a coreceptor of agrin.

Authors:  Bin Zhang; Shiwen Luo; Qiang Wang; Tatsuo Suzuki; Wen C Xiong; Lin Mei
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

9.  Lrp4 is a receptor for Agrin and forms a complex with MuSK.

Authors:  Natalie Kim; Amy L Stiegler; Thomas O Cameron; Peter T Hallock; Andrea M Gomez; Julie H Huang; Stevan R Hubbard; Michael L Dustin; Steven J Burden
Journal:  Cell       Date:  2008-10-09       Impact factor: 41.582

Review 10.  What have we learned from the congenital myasthenic syndromes.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  J Mol Neurosci       Date:  2009-08-18       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.